July 1, 2021
AbbVie said on June 30 that it has submitted its JAK inhibitor Rinvoq (upadacitinib) in Japan for an additional indication for the treatment of patients with ankylosing spondylitis (AS) who are inadequately controlled with existing therapies. The filing is based...read more